Liposomal-polyene preliposomal powder and method for its preparation by Lenk, Robert P. et al.
United States Patent 05
Lenket al.
OTNAAUS005178875A
[11] Patent Number: 5,178,875
' [45] Date of Patent: Jan. 12, 1993
 
[54]
75]
[73]
[21]
[22]
[51][52]
[58]
[56]
LIPOSOMAL-POLYENE PRELIPOSOMAL
POWDER AND METHODFORITS
PREPARATION
Inventors: Robert P. Lenk, New Waverly;
Reeta Mehta; Gabriel
Lopez-Berestein, both of Houston,all
of Tex.
Assignee: The Board of Regents, The University
of Texas System, Austin, Tex.
Appl. No.: 640,707
 
Filed: Jan. 14, 1991
Int. C1...... A61K 37/22
WLS, Cl. ceeccescsscesensseeeseeessosensees 424/450; 264/4.1;
428/402.2; 428/402.21
Field of Search ..........-.sesso 424/450; 264/4;
428/402.2, 402.21; 514/31
References Cited
U.S. PATENT DOCUMENTS
4,229,360 10/1980 Schneider... 260/403
  
 
4,247,411 1/1981 Vanlerberghe . . 252/316
4,311,712 1/1982 Evanset al. .... 424/450 X
4,370,349 1/1983 Evans .....ccccssessssesesesessees 424/450 X
4,673,567 6/1987 JiZOMOLO. .....ceecesereerssrenesenes 424/450
4,687,762 8/1987 Fukushima............:ccseeeeees 514/34 ©
4,744,989 5/1988 Payne.et al. ......sree 424/490
4,744,989 5/1988 Payne .........csscsssscceerseereees 424/490
4,762,720 8/1988 FiZOMOLO .......secereererseseseeees 424/450
4,766,046 8/1988 Abra onsstessteeeseeeeees 424/450
4,812,312 3/1989 Lopez-Berestein................ 424/417   
 
  
 
4,830,858 5/1989 Payne .....sessere .. 424/450 X
4,880,635 11/1989 Janoff et al...cseeserreecens 424/450
4,883,665 11/1989 Miyazimaetal. . 424/450 X
4,897,355 1/1990 Eppstein...scsesccseere 435/240.2
4,935,171 6/1990 Bracken .... « 424/450 X
4,950,432 8/1990 Mehta etal....... . 424/450 X
4,963,362 10/1990 Rahmanet al... 424/450
4,994,213 2/1991 Aitcheson etal. ........... 424/450 X
FOREIGN PATENT DOCUMENTS
WO89/03208 4/1989 PCT Int'l Appl. .
Primary Examiner—Thurman K. Page
Attorney, Agent, or Firm—Arnold, White & Durkee
{57] ABSTRACT
‘A methodis disclosed for preparing a stable preliposo-
mal powder which, when reconstituted with water or
saline solution, forms a suspension of liposomescontain-
ing a polyene drug, such as nystatin. The method in-
volves the steps of combining at least one phospholipid
with a first organic solvent to form a first solution,
adding a clarifying amountof waterto the first solution,
combining a polyene with a second organic solvent to
form a second solution, combining thefirst and second
solutions to produce a substantially clear combined
solution, and then removing the organic solvents, leav-
ing a powder.
68 Claims, No Drawings
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LIPOSOMAL-POLYENE PRELIPOSOMAL
POWDER AND METHODFOR ITS
PREPARATION
BACKGROUNDOF THE INVENTION
The present invention relates to a method of prepar-
ing a freeze-dried powder, which can be used to quickly
and conveniently generate a liposomal formulation of a 1
polyene such as nystatin.
Nystatin is a tetraene-diene polyene antibiotic, first
isolated from Streptomyces noursei, which is used in the
treatment of various fungal infections. Unfortunately,
nystatin, as well as other polyenes, is not generally
useful for parenteral administration, because ofits high
toxicity and insolubility in water. A formulation of a
polyene, such as nystatin, which could be administered
parenterally would substantially enhance the drug’s
therapeutic usefulness.
Some of the inventors of this patent previously dis-
covered that these problems could be overcome by
formulating nystatin in phospholipid vesicles, or lipo-
somes. Such a liposomal formulation is considerably
less toxic to the animal to whichit is administered, but
is still effective against fungal infection, and therefore is
suitable for systemic use. U.S. Pat. No. 4,812,312 dis-
closes that invention, and is incorporated here by refer-
ence.
One drawback to some liposomal drug formulations
is their less-than-desirable shelflife. Another drawback
is the relative complexity of the process needed to pre-
pare them. In view of these drawbacks, it would be
highly desirable to produce a stable, dry formulation
which could be rehydrated when needed for treatment
ofa patient. Lyophilized, or freeze-dried, powders are a
possible answer to this need. However, in order to be
practical, a lyophilized powder must not only be stable
and capable of reconstituting as liposomes, it must capa-
ble of being prepared by a process that is simple and
inexpensive enoughsothatit will be practical and cost-
effective for commercial use.
The present invention solves these and other prob-
lems foundin the priorart.
SUMMARYOF THE INVENTION
The present invention generally concerns a method
for producing a powdersuitable for the preparation of
polyene-containing liposomes upon suspension in an
aqueoussolution. In one aspect, the present invention
relates to a method of preparing a liposomal-polyene
preliposomal powder, comprising the steps of combin-
ing at least one phospholipid with a first organic solvent
to form afirst solution; combining thefirst solution with
a clarifying amount of water, forming a clarified first
solution; combining polyene with a second organic
solvent to form a second solution; combining theclari-
fied first solution and the second solution to produce a
substantially clear combined solution; and removing
substantially all the solvent from the combined solution.
In a preferred embodimentof this aspect of the present
invention, a method of preparing a liposomal-nystatin
preliposomal powder comprises the steps of combining
dimyristoy] phosphatidyl choline and dimyristoyl phos-
phatidyl glycerol with t-butyl alcohol to form a first
solution; combining the first solution with a clarifying
amountof water, forming a clarified first solution; com-
bining nystatin with dimethyl sulfoxide to form a sec-
ond solution; combining the clarified first solution and
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the second solution to produce a substantially clear
combined solution; and removing substantially all the
t-butyl alcohol and dimethy! sulfoxide from the com-
bined solution.
In another aspect, the present invention relates to a
method of preparing a parenterally-administrable poly-
ene preparation, comprising the steps of combining at
least one phospholipid with a first organic solvent to
0 form a first solution; combiningthe first solution with a
clarifying amount of water, forming a clarified first
solution; combining polyene with a second organic
solvent to form a second solution; combining the clari-
fied first solution and the second solution to produce a
substantially clear combined solution; removing sub-
stantially all the solvent from the combined solution,
thereby forming a preliposomal powder; and adding a
pharmaceutically acceptable solvent to the preliposo-
mal powder.
‘In another aspect, the present invention relates to a
liposomal-polyene preliposomal powder prepared by a
method comprising the steps of combining at least one
phospholipid with a first organic solvent to form first
solution; combining the first solution with a clarifying
amount of water, forming clarified first solution; com-
bining polyene with a second organic solvent to form a
second solution; combining the clarified first solution
and the second solution to produce a substantially clear
combined solution; and removing substantially all the
solvent from the combined solution, leaving a
preliposomal powder. A particular embodimentof this
aspect of the present invention is a lyophilized nystatin
powder, comprising nystatin, dimyristoyl phosphatidy!
choline, and dimyristoyl phosphatidyl glycerol, where
the weight ratio of DMPC to DMPGis about 7:3, and
where the powderis free of halogenated solvents. It is
believed that the relative proportions of water and the
first organic solvent affect the nature and characteristics
of the resulting powder, including the way in which the
powder behaves when hydrated. The polarity of the
- solution, with the proportion of water preferably being
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no greater than the proportion of the first organic sol-
vent, is believed to affect the organization ofthe materi-
als in solution, and thus the nature of the powderthatis
ultimately formed.
In another aspect, the present invention relates to a
substantially clear, filterable polyene solution, compris-
ing at least one polyene, at least one phospholipid,at
least one organic solvent, and a clarifying amount of
water.
The presentinvention,in its various aspects, provides
surprising advantages over the prior art. For example,it
has been found that merely combining phospholipids
with an organic solvent such as t-butyl alcohol pro-
duces a solution that is not clear, and therefore is not
desirable for use in producing a preliposomal powder.
The present invention makes use of the surprising dis-
covery that a clarifying amount of water can be added
to the solution of polyene and organic solvent, yielding
a clear solution which is suitable for use in subsequent
steps of the method. The clarity of solution permits
substantially uniform contact between the polyene and
the phospholipids in subsequent stages. Further, the
filterability of this solution permits contaminating mi-
croorganisms to be removedreadily prior to lyophiliza-
tion. This latter point is particularly important with
respect to polyenes such as nystatin, which would not
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tolerate autoclaving as an alternate means of removing
microorganisms.
It is also surprising that the clarifying amount of
water needed for use in the methodofthe present inven-
tion can range from about 10% of the amount of the
first organic solvent(e.g., t-butyl] alcoho!) upward.It is
known that in other alcohol-lipid solutions, such large
amounts of water cannot be used without causing pre-
cipitation. For example, precipitation will result in a
solution of egg phosphatidyl choline in ethanol when
the amount of water added exceeds 30% of the volume
of alcohol.
It is also surprising that a second organic solvent,
such as dimethyl sulfoxide, can be added to the clear
solution containing the clarifying amount of water in
conjunction with the addition of polyene without caus-
ing either thelipids or the polyeneto precipitate. Again,
the surprising clarity of the final solution renders the
solution more readily filterable, and thus makes the
overall process more advantageous and economical.
Without wishing to be bound by any particular theory
to explain these surprising results, it is believed that the
first organic solvent, such as t-butyl alcohol, forms a
solvation complex with the phospholipids, a complex
that arrangesitself in a micellular configuration such
that it remains clear even in a vast excess of water or
solvent. It is also believed that the polyene arranges
itself in a complex that may be micellular in nature, in
the presence of the phospholipids.
The present invention facilitates the formulation and
reconstitution of liposomal-polyene from a degradation-
fesistant preliposomal powder. The simplicity of the
present invention makes it suitable for large-scale manu-
facturing. Further, it produces a stable powder which
can be easily stored for at least one year. In addition,
whenreconstituted, the product of the present method
forms multilamellar liposomes which have a meansize
that is suitable for administration to humans, for exam-
ple in the systemic administration of liposomal nystatin
to treat a fungal or viral infection.
DESCRIPTION OF SPECIFIC EMBODIMENTS
OF THE INVENTION
A method in accordance with the present invention
can include the following steps. First, one or more
phospholipids are combined with afirst organic solvent.
The phospholipids which can be used are those which
are suitable for the preparation of liposomes, and are
well-known to those skilled in the art. Two specific
examples that are particularly preferred in the present
invention are dimyristoyl phosphatidyl choline and
dimyristoyl phosphatidyl glycerol. The preferred
weight ratio of DMPC:DMPGis approximately 7:3.
Suitable organic solvents for use a the first organic
solvent include t-butyl alcohol. The ratio of phospho-
lipid to first organic solventis preferably between about
10 g: 160 cc and about 10 g:640 cc, and is most prefera-
bly about 10 g: 320 cc. The combination of phospholipid
and first organic solvent creates a first solution.
A clarifying amountofwater is then added to thefirst
solution, resulting in the clarification of that solution. A
“clarifying amount of water” is used in this patent to
mean an amountofwater that will be effective to clarify
the already-existing solution of phospholipid and first
organic solvent. This amount of water is preferably
equal to at least 10% by weight of the amount offirst
organic solvent in the first solution. The clarifying
amountof water can range up to 100% by weight of the
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amountoffirst orgarlic solvent, and can go even higher.
In a preferred embodiment, the volumeratio of water to
t-butyl alcohol is about 1:4. In other words, in a pre-
ferred embodiment, the ratio of phospholipid to t-butyl
alcohol to water is 10 g: 320 cc: 80 cc.
The next step is to combineat least one polyene with
a second organic solvent to form a second solution. The
ratio of polyerie to second organic solvent preferably
ranges from about 1 g: 5 cc to about 1 g: 25 cc. Suitable
polyenes include nystatin, amphotericin B, filipin, ha-
mycin, and mepartricin. Nystatin is particularly pre-
ferred. Suitable second organic solvents include di-
methy] sulfoxide (DMSO)and dimethyl formamide. In
one preferred embodimentofthe present invention, the
ratio of nystatin to DMSO is approximately 1 g: 7 cc.
Thefirst and second solutions can be filtered sepa-
rately before they are combined, for example through a
0.45 2M poresize filter cartridge. However, any con-
taminants which are present, such as microorganisms,
can usually be removedin single filtration step imme-
diately before the organic solvents are removed from
the combined solution. If the amount of contaminants
present in the combined solution causes problems with
filtration, then additionalfiltration steps can suitably be
added. .
Theclarified first solution is then combined with the
second solution to produce a substantially clear com-
bined solution. Preferably, the concentration of nystatin
in the combined solution is about 2.5-2.75 mg/ml and
the concentration of phospholipid is about 25-27.5
mg/ml. The ratio of solids to liquid in this solution is
believed to be important to the ready reconstitution of
the preliposomal powderinto liposomes when wateris
added. If the solids concentration is too high, the resul-
tant dry product is denser than optimal and does not
perform as well as desired on reconstitution.
Next, substantially all of the organic solvents are
removed from the combined solution, for example by
lyophilization, producing a preliposomal powder. The
powdercan be reconstituted into an aqueous formula-
tion of liposomal polyene by adding a pharmaceutically
acceptable solvent, such as water or saline solution.
The following is a specific example of how the pro-
cess of the present invention can be performed. The
quantities given below are for the sake of example, and
could be scaled up proportionately.
Seven g of dimyristoyl phosphatidyl choline and 3 g
of dimyristoyl phosphatidyl glycerol (Lipoid KG, Lud-
wigshafen, Germany) are transferred to a first mixing
vessel. To this vessel, 250 cc of t-buty] alcohol are
added, and the solution is mixed. This first solution is
cloudy at this point. Then, 250 cc of water are added
and mixed until dissolved, resulting in a clarified solu-
tion. Nystatin (1.1 g, American Cyanamid, Pearl River,
N.Y.) is separately transferred to a second mixing ves-
sel, and 7 cc of dimethy] sulfoxide is added. The theo-
retical amount of nystatin needed for this particular
preparation is 1 g (1:10 weight ratio of nystatin: phos-
pholipid), butit is preferred to add 110% ofthe theoret-
ically needed amount. This second solution is mixed
until dissolved, and is mixed with the first solution to
produce a combined solution, whichis clear yellow.
The combined solution is analyzed for nystatin con-
centration by a spectrophotometric assay. If needed to
correct the concentration, an appropriate volume of a
diluent, such as water, is added. ;
Next, the combined solution is passed through a ster-
ile, 0.22 4M pore size membrane, and 20 cc ofthefil-
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trate is transferred into a 100 cc vial. A lyophilization
stopperis then loosely placed onthefilled vial, and the
vial is placed into a sterile lyophilization chamber,
where the solvents are removed. While the vial is
placed into the chamber, a thermocouple probeis in-
serted into the vial, in order to be able to monitorits
temperature during the freeze-drying process. When a
plurality of vials are placed in the chamber, thermocou-
ples are placed so that a reasonable cross-section of the
chamber is monitored (e.g., top, middle, and bottom of
chamber).
Thecirculating fluid in the freeze-drying chamberis
adjusted to —45° C. The chamberis then evacuated to —
a vacuum of no more than 200 microns. Thecirculating
fluid temperature is then ramped to 10° C. over a mini-
mum of about 24 hours at an approximate rate of 2.3°
C./hour. The chamber vacuum is adjusted to sweep
slowly from 60 to 100 microns using N to control the
sweep rate. When the coldest thermocouple reaches
—5° C., the circulating fluid is ramped to 28° C. over a
minimum of four hours at an approximate rate of 5.5°
C./hour. When the coldest thermocouple reaches 28°
C., the productis at terminal drying temperature, andis
held there for about 12-30 hours. At the end ofthis
time, the chamber is adjusted to atmospheric pressure
using N and NF passed through a microbiologically
retentive filter. Prior to unloading the freeze-drying
chamber, the temperature of the circulating fluid is
adjusted to 25° C. At the endofthe lyophilization cycle,
the vials are filled with nitrogen gas and the stoppers are
fully closed. The lyophilized powder appearspale yel-
low, and containsless than 2% residual t-buty] alcohol
and less than 1% residual dimethy] sulfoxide.
The formulation is reconstituted by adding about 50
cc of water to the powderfor every 1 g of polyene. It
is preferred to heat the solution above 27° C., most
preferably between about 30° and 45° C. for about
15-60 minutes, to aid the hydration process. The pow-
derinitially disperses into clumps several tens of w in
diameter. When the solution is warmed, the clumps
hydrate and spontaneously form liposomes. The tem-
perature at which this transition occurs may be due to
the phasetransition temperature of the lipids, which for
the above-described materials is around 23° C.
After reconstitution, the mean particle size is about
2-3 ».M,with not more than 1% having a diameter over
8 uM. The incorporation efficiency of drug in lipo-
somesis greater than 90%, and may approach 100%.
The preceding descriptionis intendedto illustrate the
presentinvention.It is not intended to be an exhaustive
list of all possible embodiments of the invention. Per-
sons skilled in this field will recognize that modifica-
tions could be madeto the description given above that
would remain within the scope of the invention.
Weclaim:
1. A method of preparing a liposomalpolyene
preliposomal powder, comprising the steps of:
a. combining at least one phospholipid with t-butyl
alcohol to form afirst solution;
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e. removing substantially all the solvent from the
combined solution by lyophilization.
2. The methodof claim 1, where the amount of water
effective to clarify the first solution is equal to at least
10% by volume of the amountoft-butyl alcohol.
3. The method of claim 1, where the organic solvent
ofstep (c) is dimethyl] sulfoxide.
4. The method of claim 1, where the phospholipids
are dimyristoyl phosphatidyl choline an dimyristoyl
phosphatidyl glycerol.
5. The method of claim4, wherein theratio of dimy-
ristoy] phosphatidyl choline to dimyristoy! phosphati-
dyl glycerol is about 7:3 by weight.
6. The methodofclaim 1, wheretheratio of phospho-
lipid to t-butyl alcohol is between about 10 g: 160 cc and
about 10 g: 640 cc.
7. The method of claim 1, where the ratio of polyene
to the organic solvent of step (c) is between about'l g:
5 cc and about | g: 25 cc.
8. A method of preparing a liposomalnystatin
preliposomal powder, comprising the stepsof:
a. combining at least one phospholipid with t-buty]
alcohol to form first solution;
b. combining the first solution with an amount of
water effective to clarify thefirst solution, forming
a clarified first solution;
c. combining nystatin with an organic solvent se-
lected from the group consisting of dimethyl] sulf-
oxide and dimethyl formamide to form a second
solution;
d. combining the clarified first solution and the sec-
ond solution to produce a substantially clear com-
bined solution; and
e. removing substantially all the solvent from the
combinedsolution by lyophilization.
9. The method of claim 8, where the amount of water
effective to clarify the first solution is equal to at least
10% by volumeof the amountoft-butyl alcohol.
10. The method of claim 8, where the organic solvent
of step (c) is dimethyl]sulfoxide.
11. The method of claim 8, where the phospholipids
are dimyristoyl phosphatidyl choline and dimyristoyl
phosphatidy! glycerol.
12. The method of claim 11, where the ratio of dimy-
ristoyl phosphatidyl choline to dimyristoy! phosphati-
dyl glycerol is about 7:3 by weight.
13. The method of claim 8, where the ratio of phos-
. pholipid to t-butyl alcohol is between about 10 g:160 cc
55
b. combining the first solution with an amount of 60
. water effective to clarify the first solution, forming
a clarified first solution;
combining polyene with an organic solvent selected
from the group consisting of dimethyl sulfoxide
and dimethyl formamide to form a secondsolution;
d. combining the clarified first solution and the sec-
ond solution to produce a substantially clear com-
bined solution; and
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and about 10 g: 640 cc.
"14. The method of claim 8, wherethe ratio ofpolyene
to the organic solvent of step (c) is between about 1 g:
5 cc and about 1 g: 25 ce.
15. The method of claim 8, where the volumeratio of
water to t-butyl alcohol is about 1:4.
16. The method of claim 8, where the concentration
of nystatin in the combinedsolution is about 2.5 mg/ml.
17. The method of claim 8, where the concentration
of phospholipid in the combined solution is about 25
mg/ml.
18. A method of preparing a liposomal-nystatin
preliposomal powder, comprising the stepsof:
a. combining dimyristoyl phosphatidyl] choline and
dimyristoyl phosphatidyl] glycerol with t-butyl
alcoho!to form first solution;
b. combining the first solution with an amount of
watereffective to clarify the first solution, forming
a clarified first solution;
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c. combining nystatin with dimethyl sulfoxide to form
a second solution;
combining the clarified first solution and the sec-
ond solution to produce a substantially clear com-
bined solution; and
e. removing substantially all the t-butyl! alcohol and
dimethyl sulfoxide from the combined solution by
lyophilization.
19. The method of claim 18, where the amount of
watereffective to clarify the first solution is equal to at
least 10% by volumeof the amountoft-butyl alcohol.
20. The method of claim 18, wherethe ratio of-nysta-
tin to dimethy] sulfoxide is between about 1 g: 5 cc and
about 1 g: 25 ce.
21. The method of claim 18, where the ratio of dimy-
ristoyl phosphatidyl] choline and dimyristoyl phosphati-
dy! glycerol to t-butyl alcohol is between about 10 g:
160 cc and about 10 g: 640 cc.
22. The method of claim 18, where the volumeratio
of water to t-butyl alcohol is about 1:4.
23. The method of claim 18, where the concentration
of nystatin in the combined solution is about 2.5 mg/ml.
24. The method of claim 18, where the concentration
ofDMPC and DMPGin the combinedsolution is about
25 mg/ml.
25. A method ofpreparing a parenterally-administra-
ble polyene preparation, comprising the stepsof:
a. combining at least one phospholipid with t-butyl
alcohol to form a first solution;
b. combining the first solution with an amount of
water effectiveto clarify thefirst solution, forming
a clarified first solution;
c. combining polyene with an organic solvent se-
lected from the group consisting of dimethy] sulf-
oxide and dimethyl formamide to form a second
solution;
d. combining the clarified first solution and the sec-
ond solution to produce a substantially clear com-
bined solution;
e. removing substantially all the solvent from the
combinedsolution by lyophilization, thereby form-
ing a preliposomal powder; and
f. adding a pharmaceutically acceptable solvent to the
preliposomal powder.
26. The method of claim 25, where the amount of
water effective to clarify the first solution is equal to at
least 10% by volume of the amount oft-butyl alcohol.
27. The method of claim 25, where the organic sol-
vent of step (c) is dimethyl sulfoxide, and the phospho-
lipid comprises dimyristoyl phosphatidyl choline and
dimyristoyl phosphatidyl glycerol in a weight ratio of
about 7:3.
28. The method of claim 26, where the volumeratio
of water to t-butyl alcohol is about 1:4.
29. The method ofclaim 25, where the concentration
of polyene in the combinedsolution is about 2.5 mg/ml.
30. The method of claim 25, where the concentration
of phospholipid in the combined solution is about 25
mg/ml.
31. A method of preparing a parenterally-administra-
ble nystatin preparation, comprising the steps of:
a. combining at least one phospholipid with t-butyl
alcohol to form afirst solution;
b. combining the first solution with an amount of
water effective to clarify the first solution, forming
a clarified first solution;
c. combining nystatin with an organic solvent se-
lected from the group consisting of dimethyl sulf-
d.
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oxide and dimethyl formamide to form a second
solution;
d. combining the clarified first solution and the sec-
ond solution to produce a substantially clear com-
bined solution;
e. removing substantially all the solvent from the
combinedsolution by lyophilization, thereby form-
ing a preliposomal powder; and
f. adding a pharmaceutically acceptable solventto the
preliposomal powder.
32. The method of claim 31, where the amount of
water effective to clarify the first solution is equal to at
least 10% by volumeof the amountof t-butyl alcohol.
33. The method of claim 31, where the organic sol-
vent of step (c) is dimethyl sulfoxide, and the phospho-
lipid comprises DMPC and DMPGin a weightratio of
about 7:3.
34. The method of claim 33, where the volumeratio
of water to t-butyl alcohol is about 1:4.
35. The method of claim 31, where the concentration
of nystatin in the combinedsolution is about 2.5 mg/ml.
36. The method of claim 31, where the concentration
of phospholipid in the combined solution is about 25
mg/ml.
37. A method of preparing a parenterally-administra-
ble nystatin preparation, comprising the stepsof:
a. combining dimyristoyl phosphatidyl choline and
dimyristoy! phosphatidyl glycerol with t-butyl
alcohol to form a first solution;
b. combining the first solution with an amount of
watereffective to clarify the first solution, forming
a clarified first solution;
c. combining nystatin with dimethyl sulfoxide to form
a second solution;
d. combining the clarified first solution and the sec-
ond solution to produce a substantially clear com-
bined solution;
e. removing substantially all the t-butyl alcohol and
dimethyl sulfoxide form the combined solution by
lyophilization, thereby forming a preliposomal
powder; and
f. adding a pharmaceutically acceptable solventto the
preliposomal powder.
38. The method of claim 37, where the amount of
water effective to clarify the first solution is equal to at
least 10% by volumeof the amountofthe t-butyl]alco-
hol.
39. The method of claim 37, where the volumeratio
of water to t-butyl alcohol is about 1:4.
40. The method of claim 37, where the concentration
of nystatin in the combinedsolution is about 2.5 mg/ml.
41. The method of claim 37, where the concentration
of phospholipid in the combined solution is about 25
mg/ml.
42. A liposomal-polyene preliposomal powder pre-
pared by a method comprising the steps of:
a. combining at least one phospholipid with t-butyl
alcohol to form a first solution;
b. combining the ‘first solution with an amount of
water effectiveto clarify the first solution, forming
a clarified first solution;
c. combining polyene with an organic solvent se-
lected from the group consisting of dimethyl sulf-
oxide and dimethyl] formamide to form a second
solution;
d. combining the clarified first solution and the sec-
ond solution to produce a substantially clear com-
bined solution; and
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e. removing substantially all the solvent from the
combined solution by lyophilization, leaving a
preliposomal powder.
43. The preliposomal powder of claim 42, where the
amount effective to clarify the first solution is equal to
at least 10% by volumeofthe amountoft-butyl]alcohol.
44. The preliposomal powder of claim 42, where the
organic solvent of step (c) is dimethyl sulfoxide.
’ 45. The preliposomal powderof claim 42, where the
phospholipids are dimyristoy] phosphatidyl choline and
dimyristoy! phosphatidyl glycerol.
46. The preliposoma! powderof claim 45, where the
ratio of dimyristoy! phosphatidyl] choline to dimyristoyl
phosphatidyl glycerol is about 7:3 by weight.
47. A liposomal-nystatin preliposomal powder pre-
pared by a method comprising the steps of:
a. combining at least one phospholipid with t-butyl
alcohol to form afirst solution;
b. combining the first solution with an amount of
watereffective to clarify the first solution, forming
a clarified first solution;
c. combining nystatin with an organic solvent se-
lected from the group consisting of dimethyl sulf-
oxide and dimethyl formamide to form a second
solution;
d. combining the clarified first solution and the sec-
ond solution to produce a substantially clear com-
bined solution; and
e. removing substantially all the solvent from the
combined solution by lyophilization.
48. The preliposomal powder of claim 47, where the
amount of water effective to clarify the first solution is
equalto at least 10% by volumeofthe amountoft-butyl
alcohol.
5
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49. The preliposomal powderof claim 47, where the -
organic solvent of step (c) is dimethyl sulfoxide.
50. The preliposomal powderof claim 47, where the
phospholipids are dimyristoy] phosphatidy] choline and
dimyristoyl] phosphatidyl glycerol.
51. The preliposomal powderof claim 50, where the
ratio of dimyristoyl phosphatidy! choline to dimyristoy!
phosphatidyl glycerol is about 7:3 by weight.
52. The preliposomal powderof claim 47, where the
ratio of phospholipid to t-butyl alcohol is about 10 g:
320 cc.
53. The preliposomal powder of claim 47, where the
volume ratio of water to t-butyl alcohol is about 1:4.
54. The preliposomal powder of claim 47, where the
concentration of nystatin in the combined solution is
about 2.5 mg/ml.
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55. The preliposomal powderof claim 47, where the
concentration of phospholipid in the combined solution
is about 25 mg/ml.
56. A liposomal-nystatin preliposomal powder pre-
pared by a method comprising the steps of:
a. combining dimyristoy] phosphatidyl choline and
dimyristoyl phosphatidyl glycerol with t-butyl
alcohol to form first solution; ,
b. combining the first solution with an amount of
watereffective to clarify the first solution, forming
a clarified first solution;
c. combining nystatin with dimethyl sulfoxide to form
a second solution;
d. combining the clarified first solution and the sec-
ond solution to produce a substantially clear com-
bined solution; and
e. removing substantially all the t-butyl alcohol and
dimethyl] sulfoxide from the combined solution by
lyophilization.
57. The preliposomal powder of claim 56, where the
- amount of water effective to clarify the first solution is
equalto at least 10% by volumeofthe amount oft-butyl
alcohol.
58. The preliposomal powderof claim 56, where the
ratio of nystatin to dimethyl sulfoxide is about 1 g:7 cc.
59. The preliposomal powder of claim 56, where the
concentration of nystatin in the combined solution is
about 2.5 mg/ml, the concentration of phospholipid in
the combined solution is about 25 mg/ml, and the vol-
umeratio of water to t-butyl alcohol is about 1:4.
60. A substantially clear, filterable polyene solution,
comprising at least one polyene, at least one phospho-
lipid, t-butyl alcohol, and an amount of watereffective
to clarify the solution.
61. A substantially clear, filterable nystatin solution,
comprising nystatin, at least one phospholipid, t-butyl
alcohol, and an amount of watereffective to clarify the
solution.
62. The solution of claim 61, where the solution fur-
ther comprises dimethyl sulfoxide.
63. The solution of claim 61, where the amount of
watereffective to clarify the solution is equal to at least
10% by volumeof the amountoft-butyl alcohol.
64. The solution of claim 61, where the solution is
substantially free of halogenated solvents.
65. The solution of claim 61, where the phospholipids
are dimyristoyl phosphatidyl choline and dimyristoyl
phosphatidyl glycerol in a weight ratio of about7:3.
66. The solution of claim 61, where the volumeratio
of water to t-butyl alcohol is about 1:4.
67. The solution of claim 61, where the concentration
of nystatin in the solution is about 2.5 mg/ml.
68. The solution of claim 61, where the concentration
of phospholipid in the solution is about 25 mg/ml.
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